Trial Profile
Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Lamivudine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms TIME
- 15 May 2012 Results published in the Journal of Acquired Immune Deficiency Syndromes (1999).
- 16 Nov 2011 Planned End Date changed from 1 Oct 2013 to 1 May 2011 as reported by ClinicalTrials.gov.
- 16 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.